Abstract
Purpose:
Our aim was to identify potential biomarkers and metabolic pathways that may be used to diagnosis and treat rhegmatogenous retinal detachment associated with choroidal detachment (RRDCD) and to elucidate the etiology of RRDCD.
Methods:
We used liquid chromatography-quadrupole-time of flight/mass spectrometer (LC-Q-TOF/MS) to obtain the metabolome of vitreous from patients with rhegmatogenous retinal detachment (RRD) and RRDCD. The metaboloms from 29 vitreous samples (14 from RRD patients and 15 from RRDCD patients) were analyzed by principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). A one-way analysis of variance with a Bonferroni correction was used to test significance. Biofluid Metabolites Database and Human Metabolome Database were used to identify ions.
Results:
Metabolites were used to completely discriminate between RRD and RRDCD. PLS-DA identified 265 (VIP＞1) ions whose levels were significantly different in vitreous from patients with RRD and RRDCD. Among the 265 ions, 24 of them (23 observed in the positive mode and 1 observed in the negative mode) were identified by searching MS and MS/MS fragments in the Biofluid Metabolites Database and Human Metabolome Database. The metabolites were associated with pathways related to proliferation, inflammatory reactions and hemodynamic changes.
Conclusions:
Metabolites were found that discriminated between RRDCD and RRD. Theses metabolites are likely to be involved in the pathology of the diseases and may potentially be used to diagnosis and treat RRDCD and RRD.